Rural and free-standing cancer hospitals will not get access to voluntary 340B pricing on Bristol Myers Squibb’s expensive myeloma drugs Revlimid, Pomalyst, and Thalomid under a policy change the company announced last month.
Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs
Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.